SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.4
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$26.20

18 Nov
2024

0.310

OPEN

$25.86

1.20%

HIGH

$26.27

887,022

LOW

$25.79

TARGET
$27.702 5.7% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx 107.4 108.9 xxx
DPS (cps) xxx 106.0 106.8 xxx
EPS Growth xxx - 26.4% 1.5% xxx
DPS Growth xxx 1.9% 0.7% xxx
PE Ratio xxx N/A 25.7 xxx
Dividend Yield xxx N/A 3.8% xxx
Div Pay Ratio(%) xxx 98.7% 98.0% xxx

Dividend yield today if purchased 3 years ago: 2.58%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.79

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx107.4
DPS All xxxxxxxxxxxxxxx106.0
Sales/Revenue xxxxxxxxxxxxxxx8,652.2 M
Book Value Per Share xxxxxxxxxxxxxxx1,648.8
Net Operating Cash Flow xxxxxxxxxxxxxxx1,071.5 M
Net Profit Margin xxxxxxxxxxxxxxx5.91 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx6.53 %
Return on Invested Capital xxxxxxxxxxxxxxx4.59 %
Return on Assets xxxxxxxxxxxxxxx3.53 %
Return on Equity xxxxxxxxxxxxxxx6.53 %
Return on Total Capital xxxxxxxxxxxxxxx4.68 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx101.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx661 M
Long Term Debt xxxxxxxxxxxxxxx3,854 M
Total Debt xxxxxxxxxxxxxxx4,515 M
Goodwill - Gross xxxxxxxxxxxxxxx8,502 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx645 M
Price To Book Value xxxxxxxxxxxxxxx1.60

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx579.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx6,604 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,496 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx198 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

24/10/2024

4

Lighten

$23.50

-10.31%

As a read through for Sonic Healthcare's US business, Ord Minnett notes the recent quarterly result for peer Quest Diagnostics revealed operating profit margins were under pressure. 

Elevated wage inflation rates compared to pre-covid levels continue to weigh for Quest, notes the analyst.

Management did, however, reiterate expectations for mid-single-digit revenue growth, which aligns with the broker's long-term forecast for Sonic in the US.

The $23.50 target and Lighten rating are maintained.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

24/10/2024

3

Neutral

$25.88

-1.22%

Channel checks conducted by Jarden indicate that September was another very strong month for the diagnostics space following the strength of the July and August Medicare data, which augers well for upcoming AGM's.

The broker's key pick in the ASX Diagnostics sector is Integral Diagnostics aided by the proposed merger with Capitol Health ((CAJ)) and the deregulation of MRI licences.

For Sonic Healthcare, the $25.88 target and Neutral rating are maintained.

FORECAST
Jarden forecasts a full year FY25 dividend of 103.00 cents and EPS of 108.00 cents.
Jarden forecasts a full year FY26 dividend of 108.20 cents and EPS of 130.70 cents.

SHL STOCK CHART